Key result
In patients with aortic valve stenosis undergoing transcatheter aortic valve replacement, the presence of TET2-mediated clonal hematopoiesis was associated with poorer long-term survival.
Why the study?
Does the presence of specific CHIP mutations (e.g., TET2) reduce long-term survival in patients with severe aortic valve stenosis undergoing TAVR?
Does the presence of specific CHIP mutations (e.g., TET2) reduce long-term survival in patients with severe aortic valve stenosis undergoing TAVR?
TET2-mediated clonal hematopoiesis of indeterminate potential (CHIP) may serve as a novel prognostic indicator for higher long-term mortality following TAVR.
[Figure: see text]
No takes yet. Share an insight, caveat, or question.
Evans et al. (2023) conducted an editorial in Aortic Valve Stenosis (AVS) (n=258). Clonal hematopoiesis of indeterminant potential (CHIP), specifically TET2 mutations vs. Patients without CHIP or with CHIP but without TET2 mutations was evaluated on Long-term survival after TAVR. In patients with aortic valve stenosis undergoing transcatheter aortic valve replacement, the presence of TET2-mediated clonal hematopoiesis was associated with poorer long-term survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: